🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Arthritic Psoriasis

The Norwegian Antirheumatic Drug Register NCT01581294n/a6 sites📍 Drammen📍 Lillehammer📍 Førde Diakonhjemmet Hospital A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis NCT06807424Phase 3236 sites📍 Glendale📍 Mesa📍 Jonesboro Janssen Research & Development, LLC · Tests: Icotrokinra, Placebo Novel Complex Radiodiagnostics of Peripherial Arthropathies NCT05657847n/a3 sites📍 Budapest📍 Budapest📍 Budapest Semmelweis University · Tests: Photon-counting detector-CT Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist NCT04800289n/a1 site📍 Le Mans Centre Hospitalier le Mans · Tests: questionnaires HIPPOCRATES Prospective Observational Study NCT05858528n/a1 site📍 Oxford University of Oxford · Tests: PEST screening questionnaire Swiss Dermatology Network of Targeted Therapies (SDNTT) NCT01706692n/a6 sites📍 Aarau📍 Basel📍 Bern Swiss Dermatology Network for Targeted Therapies · Tests: Adalimumab, Etanercept, Infliximab, Ustekinumab, Cyclosporine A Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. NCT07858591n/a1 site📍 Bursa Bursa Yuksek Ihtisas Training and Research Hospital · Tests: OCTA-SCP, OCTA-DCP, OCTA-RPC, OCTA-FAZ Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031NA1 site📍 Lille University Hospital, Lille · Tests: Biobanking with genetic analysis, SF-12 questionnaire A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults NCT07290036Phase 163 sites📍 Peoria📍 Apple Valley📍 Covina UCB Biopharma SRL · Tests: Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc APACHE Cohort (A Psoriatic Arthritis CoHort) NCT03768271n/a3 sites📍 Créteil📍 Montpellier📍 Paris Assistance Publique - Hôpitaux de Paris Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons NCT03248284n/a2 sites📍 Odense📍 Silkeborg Odense University Hospital · Tests: Tendon biopsy procedure Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications NCT04846959n/a2 sites📍 Morrisville📍 Wilmington AbbVie · Tests: Risankizumab, Comparator REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases NCT07160231Phase 47 sites📍 Nijmegen📍 Maastricht📍 Tilburg Sint Maartenskliniek · Tests: JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders NCT07180537NA1 site📍 Iowa City Terry L. Wahls · Tests: Creating Health Online Course, Delayed access to Creating Health Online Course Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578Phase 12 sites📍 Charlestown📍 Birtinya Seismic Therapeutic AU Pty Ltd · Tests: S-4321 Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis NCT07286058Phase 378 sites📍 Tucson📍 Fountain Valley📍 La Mesa Takeda · Tests: Zasocitinib Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis NCT05954364n/a1 site📍 Toronto Women's College Hospital Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty NCT07138898Phase 21 site📍 New York NYU Langone Health · Tests: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis NCT06865105Phase 237 sites📍 Huntington Beach📍 Avon Park📍 Clearwater AbbVie · Tests: Lutikizumab, Risankizumab Preventing Structural Damage in Early Psoriatic Arthritis NCT07486843Phase 41 site📍 Hong Kong Chinese University of Hong Kong · Tests: Amgevita 40Mg Solution for Injection, Methotrexate (Metoject® prefilled pen) Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor NCT07166315n/a1 site📍 Bath Adelphi Real World · Tests: observational study A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants NCT06663332Phase 351 sites📍 Atlanta📍 Atlanta📍 Indianapolis Janssen Research & Development, LLC · Tests: Guselkumab AYLo - AutoimmunitY and Loss of y NCT06696027n/a1 site📍 Bonn University of Bonn · Tests: Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex… Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial NCT07111494Phase 41 site📍 Milwaukee Medical College of Wisconsin · Tests: GLP-1 agonists, Nutrition Counseling A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis NCT06869551Phase 348 sites📍 Lancaster📍 Chicago📍 Indianapolis Bristol-Myers Squibb · Tests: Deucravacitinib, Placebo Evaluation of IL 12B Genetic Polymorphism (rs3213094) NCT07128472NA1 site📍 Qina South Valley University · Tests: Humira Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) NCT07611747Phase 417 sites📍 Alicante📍 Elche📍 Orihuela Instituto de Investigación Marqués de Valdecilla · Tests: Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis NCT07801495Phase 23 sites📍 Memphis📍 Colleyville📍 San Antonio Novartis Pharmaceuticals · Tests: DDY391, Placebo A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab NCT06100744Phase 334 sites📍 Little Rock📍 Washington D.C.📍 Hollywood AbbVie · Tests: Adalimumab, Risankizumab Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy NCT07150000n/a1 site📍 Bonn University of Bonn · Tests: Ex Vivo Assay
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy